High PD-L1 expression makes tumor cells more sensitive to PD-1/PD-L1 inhibitors, using PD-1 or PD-L1 antibody therapy can stimulate immune cells to “recognize” cancer cells again, thus enhancing their own immunity to attack cancer cells and significantly prolonging patient survival. This evidence concerns the gene PDCD1 and neoplasm.